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Introductory Chapter: The Journey 




The history of the process of vaccination and the concept to vaccinate is 1000 of 
year old (>3000 years) that originated in the ancient Indian peninsula (Northern 
and Eastern India) as a practice of variolation/inoculation (the immunization 
of individuals from the materials taken from the infected person) by “Woodiah” 
(Oriya) Brahmans since “time immemorial” due to its unidentifiable time of origin 
[1]. The evidence of protective measures of the process of variolation/inoculation 
is greatly described in the ancient Sanskrit text called Sacteya, mainly devoted to 
Dhanwantari, the physician [2]. Thereafter that technique may have spread to the 
China due to the transfer of education and knowledge as Chinese scholars were 
visiting the world’s oldest Universities (Nalanda and Takshashila Vishwavidyalaya 
or University). Hence the technique of variolation moved from ancient India to the 
China around 1000 CE. Thereafter, the technique of variolation traveled to Africa 
and Turkey before its arrival to the European and American continents. Before the 
introduction of variolation there was no protective measure to counter the attack 
of smallpox and the observation was made by the Greek historian Thucydides 
(430 BC) that the attack of smallpox provides protection to the person surviving the 
attack of the smallpox. Evidence indicate the first existence of smallpox as a disease 
in ancient Egypt that reveled to ancient India through Egyptian traders visiting 
India during first millennia BC [3]. From India then it traveled to China in first cen-
tury AD and reached in Japan in the sixth century AD [3]. It spread to Europe in the 
eleventh and twelfth centuries from there to North America (seventeenth century) 
and Australia (eighteenth century).
It is well established that smallpox is neither described in the Old and New 
Testaments nor in the classical Greek (including the Hippocratic and Galanus writ-
ings) and Roman literatures [2]. It was Abu Bakr Muhammad Ibn Zakariya al-Razi 
(864–930 CE), a Tehran (Iran) born Muslim physician who first differentiated 
between smallpox and the measles based on their symptoms and clinical examina-
tion of the patients [4]. However, the term smallpox is an English term for the 
disease, introduced first in India during the British rule and before it was known as 
the Masurika (For about 2000 years as mentioned in Charak and Sushruta Samhita 
before the Christian era) Basanta roga (Paproga, Sitalika, Sitala, Gunri, and Guli) or 
the spring disease in Eastern India. The concept of variolation or inoculation moved 
from India to the England in the early eighteenth century or 1721 by the British 
Lady Mary Wortley Montagu, who was living in Ottoman Empire (1716–1718) and 
communicated to her friend in Britain (Miss Sarah Chiswell, who died of smallpox 
9 years later) about this technique by letters [2, 5]. Even in 1731 one British called 
Robert Coult in Bengal wrote a letter to Dr. Oliver Coult in England describing the 
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procedure of variolation used in India to protect the local population from smallpox 
[6]. Dr. Edward Ives (1773), a British naval surgeon, also observed the procedure of 
variolation as described by the Robert Coult on his visit to India (Bengal) in 1755 [6]. 
Before the introduction of variolation/inoculation in England in the sixteenth cen-
tury the burden of infectious diseases including smallpox, measles, whooping cough, 
dysentery, scarlet fever, influenza, and pneumonia accounted for the death of more 
than 30% children of age below 15 years as the record. The concept of variolation/
inoculation was introduced in North America in 1721. By 1777, George Washington, 
ordered that all the soldiers and recruits of his army should be inoculated/variolated. 
Thus introduction of the concept of variolation was the first step towards the devel-
opment of Edward Jenner’s cowpox/smallpox vaccine, modern day vaccines, and the 
introduction of the concept of vaccination to fight against infectious diseases.
Almost all text books of immunology and microbiology mention Edward Jenner 
as a father of immunology or vaccination due to his invention of the technique called 
vaccination as he injected the cowpox immunogenic material (pus) isolated from the 
hand of Sarah Nelmes (a female milkmaid, who got the cowpox from the infected 
cow called Blossom) to the both arms of James Phipps (a young boy of 8 years) on 
May 14, 1796 [7]. However, the process of vaccination was developed almost 22 years 
before Edward Jenner by a farmer called Benjamin Jesty [7]. No one knows Benjamin 
Jesty. Even the reports are available to indicate the existence of the concept/Sanskrit 
literature of cowpox vaccine to induce the immunity against smallpox in ancient 
India. It may be an injustice to the real discoverer of the concept of cowpox vaccina-
tion but the journey of vaccines and vaccination had started that never looked back. 
However the technique of variolation banned or made illegal in Britain in 1840 and 
the Jenner’s vaccination was promote and offered free of cost [3].
2.  The development of vaccines from early nineteenth to twenty-first 
century
The early eighteenth century saw development of the vaccination procedure 
against small pox and its promotion in England by offering free vaccination there. Its 
spread all over the world revolutionized the field of vaccination against several other 
infectious diseases. However, the scientific origin of vaccines took at least a century 
following the discoveries made by Robert Koch and Louis Pasteur generating the 
concept there are pathogenic microbes/microorganisms causing infectious. Pasteur 
initiated attenuation of these pathogens in his laboratory by different methods includ-
ing drying, heating, and exposing them to oxygen or passaging them in different 
animal hosts. The first live attenuated vaccine was developed for Rabies in 1885 and 
was used to immunize a boy named Josef Meister bitten by a rabid dog [8]. Thereafter 
killed whole organisms were used to develop vaccine against cholera (1896), typhoid 
(1896), and plague (1897) [9]. In second half of the twentieth century oral polio vac-
cine (OPV, 1963), measles (1963). Mumps (1967), and rubella (1969), all live attenu-
ated vaccine came out along with several other vaccines (polio (injected, 1955), a killed 
whole organism vaccine, Anthrax vaccine (a protein-based vaccine, 1970), Hepatitis B 
surface antigen recombinant (a genetically engineered vaccine in 1986), and hepatitis 
A (a whole killed organism-based vaccine in 1996) were developed [9].
In twenty-first century, human papillomavirus (HPV) recombinant (quadriva-
lent in 2006), live attenuated vaccine Zoster in 2006, HPV recombinant (bivalent 
in 2009), pneumococcal conjugates (capsular polysaccharide conjugated with the 
career protein) (13-valent in 2010) are developed. Furthermore the live attenuated 
vaccine for the dengue virus infection is also developed by Sanofi Pasteur in 2016 
and is called CYD-TDV that is sold under the brand name Dengvaxia [10, 11]. This 
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live attenuated tetravalent chimeric vaccine is developed through the use of recom-
binant DNA technology by replacing the PrM (pre-membrane) and E (envelope) 
structural genes of the yellow fever attenuated 17D strain vaccine with those from 
four of the five dengue serotypes [11]. However this dengue vaccine is recom-
mended to the patients previously infected with dengue virus infection otherwise it 
may exert adverse effects during subsequent infections as their manufacture, Sanofi 
Pasteur. The vaccine is approved to use 11 countries including Mexico, Philippines, 
Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand 
and Singapore [12–15]. The dengue vaccine has shown consistence efficacy in 
healthy adults of Australia and ready to go in clinics [16]. The vaccine has shown 
immunogenicity and safety during a 5-year study [17] A most recent development 
in the field of vaccinology is the clinical trial for the live attenuated vaccine for Zika 
virus vaccine at the Johns Hopkins Bloomberg School of Public Health Centre for 
Immunization Research in Baltimore, Maryland, and at the Vaccine Testing Centre 
at the Larner College of Medicine at the University of Vermont in Burlington. The 
clinical trial for Zika virus is sponsored by National institute of allergy and infec-
tious disease (NIAID), USA. In addition to the development of vaccines for infec-
tious diseases these are also to develop against different cancers through targeting 
cancer-associated neoantigens.
The major aim of the book is to provide the readers an updated information on 
the field. For example, the first chapter of the book written by Dr. Raw Isaias has 
updated the progress of regarding the innovation and development of new vaccines 
and their candidates in developing countries like Brazil. In the second chapter,  
Dr. Dai has provided a great information regarding the different types of vac-
cines that will be informative for undergraduate and graduate students along with 
researchers. The third chapter of the book provides the regulatory journeys of appli-
cations with genetically modified viral vectors and novel vaccine candidates already 
reviewed by GMO (Genetically modified organisms) national competent authori-
ties in Belgium and in Europe. This chapter will be crucial for the readers interested 
in regulatory affairs for the vaccines developed via GMOs. In fourth chapter, author 
(Leunda Amaya) has given an emphasis to target the vaccination strategies wildlife 
reservoirs including bats, boars, rodents, and other carnivorous animals serving as 
reservoirs for zoonotic viral infections (Rabies, Hanta virus infection, and Hepatitis 
E virus) in humans. The fifth and last chapter of the book written by Dr. Dulcilene 
describes the development of vaccinia virus vector to develop the vaccines against 
leishmaniasis that is major problem for developing countries of Asia, Africa and 
South America. Thus the book starts with the introductory chapter regarding the 
history and present status of the vaccines along with the other chapters contributed 
by the authors known in their field. Thus book is intended to provide the current 
and updated knowledge in the field of vaccinology.
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